Second-line CAR-T therapy in B-cell lymphoma

Optimizing the Current and Future Management of Relapsed/Refractory DiffuseПодробнее

Treatment failure patterns in second-line versus third-line introduction of CAR-T therapy in LBCLПодробнее

Total Health Oncology: Best of Heme 2025 Session 2Подробнее

The current status of CAR T-cell therapy for lymphoma in the UKПодробнее

Optimizing CD19 CAR T-cell delivery for patients with R/R aggressive lymphomaПодробнее

Glofitamab plus R-ICE chemotherapy in R/R DLBCL: a Phase Ib studyПодробнее

Lymphoma Highlights from #ASH24Подробнее

Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of LymphomaПодробнее

How to best manage first relapse in DLBCL outside of CAR-TПодробнее

ASH Update on Lymphoma & CLLПодробнее

Inmunidad a la carta: células CAR-T en la lucha contra el cáncerПодробнее

SOHO Saudi Arabia 2024 (Day 1) - Dr Abdulwahab AlbabtainПодробнее

Webinaire international - YoungEHA -CAR T-cells and bi-specificsПодробнее

CAR-T Therapy and Stem cell transplant in Lymphoma patients: Current treatment landscapeПодробнее

Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with NHL and CLLПодробнее

Where do bispecific antibodies fit into the large cell lymphoma treatment landscape?Подробнее

New Approaches to Relapsed & Refractory DLBCLПодробнее

CAR-T Revolution – Advancing Lymphoma Treatment with Precision & InnovationПодробнее

How to treat Diffuse Large B-Cell Lymphoma (DLBCL) - Dr. Carla CasuloПодробнее

Second-line treatment strategies for patients with relapsed DLBCLПодробнее